ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.Annals of nuclear medicine · 2026Article
- Review
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Preclinical safety and effectiveness of a long-acting somatostatin analogue [European journal of nuclear medicine and molecular imaging · 2025Article
- Somatostatin receptor-targeted polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic hepatocellular carcinoma therapy.Journal of nanobiotechnology · 2025Article
- Abnormal uptake related to the thyroid gland on somatostatin receptor-targeted PET imaging: reported prevalence and rate of thyroid malignancy and parathyroid adenomas.Endocrine connections · 2024Article
- First preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2023Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- Developments inFrontiers in chemistry · 2023Review
- New Biology of Pheochromocytoma and Paraganglioma.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Review
- Article
- The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas.Journal of clinical medicine · 2022Review
- Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer.Frontiers in genetics · 2022Article
- Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.Frontiers in oncology · 2022Article
- Peptide Receptor Radionuclide Therapy in Thyroid Cancer.Frontiers in endocrinology · 2022Review
- Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.Cancer immunology, immunotherapy : CII · 2021Article
- Best Achievements in Clinical Thyroidology in 2020.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.Neuro-oncology advancesArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
purposeThe goal of this study was to analyze the role of somatostatin receptor type 2 (SSTR2) as a molecular target for the imaging and treatment of thyroid cancer through analysis of SSTR2 expression and its epigenetic modulation and testing tumor uptake of different radiolabeled SSTR2 analogues. EXPERIMENTAL
designWe analyzed SSTR2 expression by immunostaining of 92 thyroid cancer tissue samples and quantified standard uptake values (SUV
resultsThyroid cancer had a higher SSTR2 expression than normal thyroid. Hurthle cell thyroid cancer was characterized by the highest
conclusionsA novel SST analogue,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.